Insights into the use of biomarkers in clinical trials in Alzheimer's disease | ||
| dc.conicet.organizacion | University of Pittsburgh | |
| dc.conicet.organizacion | University of Pittsburgh | |
| dc.conicet.organizacion | University of Pittsburgh | |
| dc.conicet.organizacion | Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Instituto de Neurociencias - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Neurociencias | |
| dc.conicet.organizacion | Universidade de Sao Paulo | |
| dc.conicet.organizacion | Universitat Autònoma de Barcelona | |
| dc.conicet.organizacion | McGill University. Montreal Neurological Institute and Hospital | |
| dc.conicet.organizacion | Universidade Federal do Rio Grande do Sul | |
| dc.conicet.organizacion | University of Pittsburgh | |
| dc.conicet.organizacion | University of Pittsburgh | |
| dc.contributor.author | Pascoal, Tharick A. | |
| dc.contributor.author | Aguzzoli, Cristiano S. | |
| dc.contributor.author | Lussier, Firoza Z. | |
| dc.contributor.author | Crivelli, Lucía | |
| dc.contributor.author | Suemoto, Claudia K. | |
| dc.contributor.author | Fortea, Juan | |
| dc.contributor.author | Rosa Neto, Pedro | |
| dc.contributor.author | Zimmer, Eduardo R. | |
| dc.contributor.author | Ferreira, Pamela C .L. | |
| dc.contributor.author | Bellaver, Bruna | |
| dc.date.issued | 2024-10 | |
| dc.description.abstract | Biomarkers have been instrumental in population selection and disease monitoring in clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of Alzheimer’s disease (AD). As new therapeutic strategies and biomarker techniques emerge, the importance of biomarkers in drug development is growing exponentially. In this emerging landscape, biomarkers are expected to serve a wide range of contexts of use in clinical trials focusing on AD and related dementias. The joint FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) framework provides standardised terminology to facilitate communication among stakeholders in this increasinglycomplex field. This review explores various applications of biomarkers relevant to AD clinical trials, using the BEST resource as a reference. For simplicity, we predominantly provide contextual characterizations of biomarkers use from the perspective of drugs targeting amyloid-β and tau proteins. However, general definitions and concepts can be extrapolated to other targets. | es |
| dc.description.fil | Fil: Pascoal, Tharick A.. University of Pittsburgh; Estados Unidos | |
| dc.description.fil | Fil: Aguzzoli, Cristiano S.. University of Pittsburgh; Estados Unidos | |
| dc.description.fil | Fil: Lussier, Firoza Z.. University of Pittsburgh; Estados Unidos | |
| dc.description.fil | Fil: Crivelli, Lucía. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Instituto de Neurociencias - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Neurociencias; Argentina | |
| dc.description.fil | Fil: Suemoto, Claudia K.. Universidade de Sao Paulo; Brasil | |
| dc.description.fil | Fil: Fortea, Juan. Universitat Autònoma de Barcelona; España | |
| dc.description.fil | Fil: Rosa Neto, Pedro. McGill University. Montreal Neurological Institute and Hospital; Canadá | |
| dc.description.fil | Fil: Zimmer, Eduardo R.. Universidade Federal do Rio Grande do Sul; Brasil | |
| dc.description.fil | Fil: Ferreira, Pamela C .L.. University of Pittsburgh; Estados Unidos | |
| dc.description.fil | Fil: Bellaver, Bruna. University of Pittsburgh; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Pascoal, Tharick A.; Aguzzoli, Cristiano S.; Lussier, Firoza Z.; Crivelli, Lucía; Suemoto, Claudia K.; et al.; Insights into the use of biomarkers in clinical trials in Alzheimer's disease; Elsevier; eBioMedicine; 108; 10-2024; 1-13 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 2352-3964 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/266870 | |
| dc.journal.pagination | 1-13 | es |
| dc.journal.pais | Países Bajos | es |
| dc.journal.title | eBioMedicine | es |
| dc.journal.volume | 108 | es |
| dc.language.iso | eng | es |
| dc.publisher | Elsevier | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S235239642400358X | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.ebiom.2024.105322 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ | * |
| dc.subject | Alzheimer’s disease | es |
| dc.subject | Clinical trials | es |
| dc.subject | Biomarkers | es |
| dc.subject | Disease-modifying therapies | es |
| dc.subject.classification | Otras Ciencias de la Salud | es |
| dc.subject.classification | Ciencias de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Insights into the use of biomarkers in clinical trials in Alzheimer's disease | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.d1f607cd-f798-48e4-8acc-0ed37bb6bcf8_C.pdf
- Tamaño:
- 528.2 KB
- Formato:
- Adobe Portable Document Format
- Descripción: